Tronox: a real recovery option, but a thin equity cushion

Tronox, the integrated titanium dioxide producer, could recover substantially. But after three weak years its common equity is a thin residual behind about $3.2 billion of financing obligations, and an improving quarter is not yet evidence of sustainable owner cash flow.

At $4.40 on September 22, 2026, the shares trade 27.7% above my recovery-case Base value of $3.45. The required margin of safety works out at 70%, above the framework's 60% practical ceiling, so no buy price is issued at all. This is not a claim that Tronox cannot recover. It is a judgment that $4.40 does not protect against a recovery that arrives late, converts poorly into cash, or needs more capital.

Route: SF-13 Industrial and Manufacturing, commodity-cyclical chemicals, with a mineral resources risk overlay. Economic classification: Standard Company (1/12), leveraged cyclical recovery. Primary method: EV to normalized economic EBITDA. Secondary method: capitalized owner earnings. Values are capitalized recovery values on today's financing structure, not 12-month price targets.

What Tronox is

Tronox combines mineral sands mining and processing with titanium dioxide pigment manufacturing for paints, coatings, plastics and paper. TiO2 was $700 million of $868 million in Q2 revenue, or 80.6%, so the company is valued as a chemicals business rather than with a mine-by-mine NAV. The mining side is treated as an overlay for reserve replacement, energy, geography and sustaining investment.

The valuation uses mid-cycle economic EBITDA and cash available to equity after financing and reinvestment. Negative P/E, revenue multiples alone, peak EBITDA, book value and a permanently annualized inventory release are rejected. No separate value is included for the downstream rare earth project: a definitive feasibility study is expected in Q3 2027, and financing, timing and returns are unresolved.

Financial performance through the cycle

$ million.

The five-year EBITDA average is $649.2 million, the latest three-year average $474.7 million. Five-year average FCF is $42 million, the latest three-year average minus $142.7 million. Revenue declined about 5.1% a year from 2021 to 2025.

The Base case of $650 million is therefore a recovery case, roughly the five-year average, and above the recent three-year norm. Against the TTM period, only $16.8 million of the $384 million EBITDA improvement comes from revenue growth. The other $367.2 million requires margin recovery, so the thesis is about spreads, utilization and costs, not simply higher sales.

Management guides 2026 cash interest of about $190 million and capex below $260 million. Q3 2026 EBITDA guidance is $95 to $115 million, against $73 million in Q2.

Cash flow quality

These three measures must not be confused. Removing only the inventory release ignores offsetting receivables and payables, while removing the full working capital movement and then subtracting the securitization expansion again would count it twice. Q2 FCF of $60 million benefited from about $101 million of working capital, and without it the quarter was about minus $41 million after capex. None of this is annualized.

The Base model turns $650 million of company Adjusted EBITDA into only $65 million of owner earnings, a 10% conversion. That conversion, not an attractive headline EBITDA multiple, drives the verdict.

Debt, shares and the equity bridge

The $75 million sale and leaseback is a financing obligation, and its proceeds are already in reported cash, so they are not added again. Known subsequent financing moves reduce cash and obligations by the same amount, so they create no improvement in net financing. June liquidity was $527 million, including $194 million of cash; undrawn facilities are not cash. The 2029 maturity concentration buys time but does not remove refinancing risk.

The share count is 159.7 million plus 3.19 million restricted stock units excluded from loss-period diluted EPS, rounded up to 163 million. An ongoing $20 million stock compensation charge keeps later awards share-neutral, rather than also assuming annual dilution. No shares were repurchased in H1.

Primary valuation: economic EBITDA

Divided by 163 million shares, the primary Base value is $3.51. The 6.5x multiple is the midpoint of the framework's 5x to 8x commodity-industrial band, applied to a harder denominator than company Adjusted EBITDA, and is not a verified peer median. The $30 million legacy allowance is uncertain: undiscounted retirement and environmental commitments include about $30 million due within a year, plus pension and longer-dated costs.

Secondary valuation: owner earnings

At 9x, less the $30 million minority adjustment, common equity is $555 million, or $3.40 per share. Net debt is not subtracted again because these earnings already follow interest. Interest of $205 million adds a $15 million cushion to the roughly $190 million guidance. Capex of $275 million sits above the one-year outlook but below the five-year average, a judgment about renewal needs rather than a verified maintenance split. Cash taxes are modeled at $10 million plus 25% of profit above $300 million of depreciation and interest, so today's low cash taxes are not assumed forever.

Historical cross-check

Historical positive-FCF equity multiples were about 7.9x in 2021 and 12.5x in 2022, with no meaningful figure for 2023 to 2025. The 9x owner earnings multiple lies between them, but two data points on a different cash definition and debt burden are weak evidence. No peer discount is claimed, because a synchronized peer set on the same economic EBITDA basis is not available.

Valuation triangulation

The cash method gets more weight because this balance sheet needs cash after reinvestment and financing, not just EBITDA recovery. The methods diverge by only 2.9%, but they share the same capex, margin and legacy cost risks. Two models can agree and still both be wrong about sustainable earnings.

What is the market already pricing in?

At $4.40, diluted market equity is $717.2 million and implied operating enterprise value $3,948.2 million. At 6.5x, that requires economic EBITDA of $607.4 million, or company Adjusted EBITDA of about $672 million. The owner earnings method implies $83 million of owner earnings, which needs about $674 million of company EBITDA. My Base is $650 million and $65 million.

The stock is not pricing a business that can never recover. It already requires sustainable EBITDA about 2.5 times the TTM figure. At $3,250 million of revenue, that means a 20.7% EBITDA margin against the Base 20.0%. A small operating disagreement becomes a large equity disagreement because debt absorbs most of the enterprise value first.

Bear, base and bull scenarios

Bear: some cyclical recovery occurs, but weak cash conversion and refinancing capacity leave no positive equity residual. Zero is a permanent loss stress outcome, not a prediction that the next quote will be zero, since option value and recovery negotiations could support a trading price. Base: pricing, utilization and cost benefits restore roughly five-year-average EBITDA while capital needs stay high. Bull: strong spreads and operating leverage approach, but do not exceed, the 2021 and 2022 peaks, with higher capex and working capital.

All scenarios use the same multiples, bridge and share count, so the uncertainty is operational rather than an arbitrary collapse of both earnings and multiples. The probabilities describe which operating condition becomes credible over roughly 24 to 36 months. The probability-weighted value is $3.67, still 16.5% below the price.

Sensitivity

This extreme sensitivity of the residual equity is the main reason not to mistake the close agreement of the two methods for high confidence.

Twelve-month price touch: illustration only

This separates touching a price from reaching a fundamental scenario. It assumes zero expected drift and an assumed, not measured, 80% annual volatility, with a 60% to 100% range, and ignores default jumps and dilution. The events can overlap and do not add up to 100%.

Why there is no buy price

Above its 60% practical ceiling, the framework prefers a NO-BUY or WATCHLIST verdict to publishing a deceptively precise bargain price. No maximum buy price and no buy zone are issued. For orientation only, a 60% discount to Base would give $1.38. That is not the real 70% requirement and must not be used as an automatic order or price alert.

Re-underwriting needs evidence of sustainable positive cash after reinvestment, financing stability and less reliance on monetizing operating assets. A higher share price with genuinely stronger fundamentals could be more investable than a lower price after new financing distress.

Dividend

The quarterly dividend is $0.05, or $0.20 a year, an indicated 4.55% yield at $4.40, with the current payment due October 9, 2026. The quarterly rate fell 60% from $0.125 in Q4 2024 to $0.05 by Q4 2025. Trailing FCF is negative, so coverage is not established. In the recovery Base, the roughly $32 million annual dividend would take about half of owner earnings before minority considerations and scheduled principal. Tronox is not a reliable dividend income anchor.

Reasons to follow TROX

• Integrated assets. Recovery does not require building a platform from scratch. Existing extraction, feedstock and pigment operations offer operating leverage when economics improve.
• Large recovery potential. The Bull case uses $850 million of EBITDA, below the reported 2021 and 2022 results, not an unprecedented earnings level.
• Corrective actions. Plant closures and cost programmes could reduce cash leakage, and recent quarterly guidance has been met.
• Time and options. The maturity profile and existing financing access give room to repair the balance sheet, and rare earths could add value without being needed for the Bull case.

These are reasons a specialist might research a speculative position. They do not establish a margin of safety at $4.40.

What could go wrong?

• Cash conversion. Higher sales and EBITDA fail to produce cash after investment and financing, and inventory and receivables monetization cannot keep adding cash indefinitely.
• Refinancing or dilution. Credit pressure could force expensive borrowing, asset sales or equity issuance before normalization. Ratings disclosed with Q2 were Moody's B3 negative and S&P CCC+ positive.
• Structurally lower margins. Pricing, energy, logistics and utilization may prevent a return to a 20% EBITDA margin, and the Base already needs a significant recovery.
• Competing claims on cash. Renewal spending, remediation, pensions and new projects may exceed the modeled allowances.

Management execution

Commodity conditions explain part of the misses, but long-range targets deserve a discount. The announced $125 to $175 million end-2026 savings run rate is not added wholesale to an EBITDA base that already contains some of it. Management credibility: forecasting 1/5, capital discipline 2/5, cash consistency 2/5, corrective execution 3/5, for 8/20, a mixed record.

Stock Analyza scorecard

As a cross-check, economic EBIT of $285 million taxed at 25% gives about $214 million of NOPAT, a 4.6% to 5.1% return on an estimated $4.2 to $4.6 billion capital base, below an assumed 9% to 11% hurdle. This is a model proxy, not a reported ROIC.

Under the framework's classification, the stock is slightly overvalued.

Confidence score

There is more confidence that downside protection is insufficient than in the exact $3.45 estimate. The data do not establish imminent insolvency. They establish insufficient resilience for a routine value purchase.

What I would watch from here

The next review point is Q3 2026 earnings and the accompanying 10-Q.

The three most important thesis breakers

1. Sustained cash losses despite a reported recovery.
2. Restricted or materially more expensive access to financing.
3. Investment obligations or dilution that transfer recovery value away from existing shareholders.

Adversarial review

Two separately written arithmetic implementations recomputed every scenario, the sensitivity grid, the reverse model, the weights and the scores. The review corrected errors in both directions. It added the omitted inventory financing and sale and leaseback, the minority interest and the excluded restricted stock units, and raised the legacy cost allowance from $15 to $30 million, all of which lowered value. It also replaced GAAP interest with cash interest and corrected an overly negative working capital reading, which raised value.

The strongest counter-thesis is that a depressed price buys operating leverage before the recovery is obvious: past earnings show the upside, cash guidance is improving, maturities are not immediate and lower capex could lift equity cash sharply. It is credible and was tested. But normalizing to five-year average EBITDA already embeds much of it, and debt and owner cash still constrain the Base.

The no-new-buy verdict survives every test except the generous recovery case, which requires a much stronger state than the Base. A categorical claim that the equity has no value would therefore be unsupported. The narrower conclusion is that the Base and the downside protection do not support a routine purchase at $4.40. These are capitalized recovery values, not forecasts for a particular date, and further years of losses or equity financing would need a new analysis. The publication gate status is PASS_WITH_WARNING.

Final verdict: watchlist, no new buy at $4.40

A Tronox recovery could reward a speculative investor very substantially. But the current price does not compensate for the financing and cash conversion risks. The conservative choice for new money is to wait for evidence rather than treat a low share price or a dividend yield as proof of value.

Verdict: WATCHLIST, NO NEW BUY at $4.40. Triangulated Base value $3.45, downside 21.7%, Confidence D (11/25). The required 70% margin of safety exceeds the framework's practical ceiling, so no maximum buy price is issued.

For an existing position, the conclusion is to reassess its speculative risk budget, not to average down automatically. A sale decision would also depend on position size, taxes and tolerance for permanent loss.

The main thesis breaker is another period of negative financing-adjusted FCF that forces materially more expensive funding or dilutive equity before margin recovery becomes durable.

Sources

Primary sources include Tronox's Q2 2026 results, June 2026 Form 10-Q, Q2 2026 earnings presentation, Q1 2026 results, 2025 Form 10-K and full-year results for 2021, 2022, 2023, 2024 and 2025. Dividend history comes from the Q4 2024, Q4 2025 and Q3 2026 declarations, and the business description from the company overview. Historical equity multiples are from a third-party market data aggregator and serve only as a secondary cross-check.

The reference market price is $4.40, the latest trade at 4:30 pm EDT on September 22, 2026, after the regular session, not a closing price. Balance sheet figures are as of June 30, 2026.